Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 February 2019Website:
http://hoththerapeutics.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
HOTH Latest News
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology.
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial NEW YORK , Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
Cancer Patient Ceased Treatment After One Week Due to Rapid Success In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days.
Hoth Therapeutics (NASDAQ: HOTH ) stock is on the move Wednesday after the clinical-stage biopharmaceutical company announced a new partnership with LTS Therapy Systems. This partnership has the two companies working together to accelerate the development of Hoth Therapeutics' candidate for Alzheimer's disease.
Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health NEW YORK , July 16, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharmaceutical company, today announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). "We are very pleased to have received approval from these three world class medical centers for our FIH clinical trial," said Hoth Therapeutics Chief Executive Officer, Robb Knie.
Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.
Hoth Therapeutics (NASDAQ: HOTH ) stock is rocketing higher on Tuesday thanks to the company announcing positive results from a preclinical trial. According to a Hoth Therapeutics press release, these results come from its study of HT-ALZ as a treatment for Alzheimer's disease.
What type of business is Hoth Therapeutics?
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
What sector is Hoth Therapeutics in?
Hoth Therapeutics is in the Healthcare sector
What industry is Hoth Therapeutics in?
Hoth Therapeutics is in the Biotechnology industry
What country is Hoth Therapeutics from?
Hoth Therapeutics is headquartered in United States
When did Hoth Therapeutics go public?
Hoth Therapeutics initial public offering (IPO) was on 15 February 2019
What is Hoth Therapeutics website?
https://hoththerapeutics.com
Is Hoth Therapeutics in the S&P 500?
No, Hoth Therapeutics is not included in the S&P 500 index
Is Hoth Therapeutics in the NASDAQ 100?
No, Hoth Therapeutics is not included in the NASDAQ 100 index
Is Hoth Therapeutics in the Dow Jones?
No, Hoth Therapeutics is not included in the Dow Jones index
When was Hoth Therapeutics the previous earnings report?
No data
When does Hoth Therapeutics earnings report?
The next expected earnings date for Hoth Therapeutics is 13 November 2024